• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>NCI

NCI

NCI Inc Class A NCIT

Last Price$8.98Day Change (%)5.77%
Open Price$8.44Day Change ($)0.49
Day Range8.03–8.9952-Week Range4.47–13.12

As of Thu 07/31/2014 02:57 PM EST | USD

  1. McGraw Hill Financial Reports 2nd Quarter Results

    McGraw Hill Financial Reports 2nd Quarter Results

  2. U.S. FDA Grants Regular (Full) Approval for IMBRUVICA® for Two Indications

    U.S. FDA Grants Regular (Full) Approval for IMBRUVICA® for Two Indications

  3. Aflac and The University of Texas MD Anderson Cancer Center Honor Three Leaders in Fight Against Childhood Cancer

    Aflac and The University of Texas MD Anderson Cancer Center Honor Three Leaders in Fight Against Childhood Cancer

  4. Terex Announces Second Quarter 2014 Results

    Terex Announces Second Quarter 2014 Results

  5. FDA Grants Genentech’s Avastin Priority Review for Certain Types of Cervical Cancer

    FDA Grants Genentech’s Avastin Priority Review for Certain Types of Cervical Cancer

  6. Exelixis Announces Positive Top-Line Results for Phase 3 Pivotal Trial of Cobimetinib in Combination With Vemurafenib in Patients With BRAF V600 Mutation-Positive Advanced Melanoma

    Exelixis Announces Positive Top-Line Results for Phase 3 Pivotal Trial of Cobimetinib in Combination With Vemurafenib in Patients With BRAF V600 Mutation-Positive Advanced Melanoma

  7. Oncolytics Biotech® Inc. Announces Completion of Patient Enrollment in U.S. Randomized Phase II Pancreatic Cancer Study

    Oncolytics Biotech® Inc. Announces Completion of Patient Enrollment in U.S. Randomized Phase II Pancreatic Cancer Study

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.